Anti-Cancer Agents in Medicinal Chemistry

metrics 2024

Advancing cancer therapeutics through innovative chemistry.

Introduction

Anti-Cancer Agents in Medicinal Chemistry is a pivotal journal in the realm of cancer research, published by Bentham Science Publishers in the United Arab Emirates. With an ISSN of 1871-5206 and an E-ISSN of 1875-5992, this esteemed journal has been disseminating high-quality research since its inception in 2006, and is set to continue through 2024. The journal is categorized in the third quartile (Q3) across key areas including Cancer Research, Molecular Medicine, and Pharmacology, highlighting its essential role in providing valuable insights to the scientific community. Despite its open-access status being unspecified, researchers benefit from the rigorous peer-review process ensuring the publication of significant advancements. The journal ranks well within Scopus, particularly in the fields of Pharmacology and Cancer Research, which positions it as a notable resource for professionals, students, and researchers aiming to deepen their knowledge in anti-cancer strategies. Through its comprehensive scope, the journal aims to bridge the gap between medicinal chemistry and clinical applications, making it an indispensable tool for those dedicated to advancing cancer therapeutics.

Metrics 2024

SCIMAGO Journal Rank0.50
Journal Impact Factor2.60
Journal Impact Factor (5 years)2.50
H-Index108
Journal IF Without Self2.60
Eigen Factor0.00
Normal Eigen Factor0.76
Influence0.37
Immediacy Index1.00
Cited Half Life5.70
Citing Half Life7.40
JCI0.59
Total Documents2966
WOS Total Citations5630
SCIMAGO Total Citations21891
SCIMAGO SELF Citations595
Scopus Journal Rank0.50
Cites / Document (2 Years)2.69
Cites / Document (3 Years)2.78
Cites / Document (4 Years)2.74

Metrics History

Rank 2024

Scopus

Pharmacology in Pharmacology, Toxicology and Pharmaceutics
Rank #149/313
Percentile 52.40
Quartile Q2
Cancer Research in Biochemistry, Genetics and Molecular Biology
Rank #132/230
Percentile 42.61
Quartile Q3
Molecular Medicine in Biochemistry, Genetics and Molecular Biology
Rank #105/178
Percentile 41.01
Quartile Q3

IF (Web Of Science)

CHEMISTRY, MEDICINAL
Rank 44/72
Percentile 39.60
Quartile Q3
ONCOLOGY
Rank 175/322
Percentile 45.80
Quartile Q3

JCI (Web Of Science)

CHEMISTRY, MEDICINAL
Rank 46/72
Percentile 36.11
Quartile Q3
ONCOLOGY
Rank 180/322
Percentile 44.10
Quartile Q3

Quartile History

Similar Journals

MOLECULAR THERAPY

Catalyzing advancements in patient-centered molecular therapies.
Publisher: CELL PRESSISSN: 1525-0016Frequency: 12 issues/year

MOLECULAR THERAPY, published by CELL PRESS, is a distinguished journal in the field of molecular biology and therapy, renowned for its significant contributions to drug discovery, genetics, and pharmacology since its inception in 2000. This prestigious journal, which holds a commendable position in the Q1 category across multiple disciplines including Drug Discovery, Molecular Medicine, and Molecular Biology, facilitates cutting-edge research and innovative therapies that aim to improve patient outcomes. With an impressive Scopus ranking that places it among the top journals in its field—such as rank #6 in Drug Discovery and #8 in Pharmacology—MOLECULAR THERAPY is crucial for researchers, professionals, and students seeking to advance their understanding and application of molecular techniques. The journal welcomes high-quality submissions that explore the therapeutic potential of molecular mechanisms, fostering a collaborative spirit within the scientific community to push the boundaries of modern medicine.

INTERNATIONAL JOURNAL OF ONCOLOGY

Pioneering innovative practices in cancer treatment.
Publisher: SPANDIDOS PUBL LTDISSN: 1019-6439Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.

Fitoterapia

Advancing Knowledge in Medicinal Plant Research
Publisher: ELSEVIERISSN: 0367-326XFrequency: 8 issues/year

Fitoterapia is a prestigious journal published by Elsevier that specializes in the fields of drug discovery and pharmacology. Established in 1948 and featuring a comprehensive scope that encompasses all aspects of medicinal plants and their derivatives, this journal is a critical resource for researchers, professionals, and students interested in the pharmacological effects of natural products. With an impressive impact factor reflected in its Q2 ranking in both Drug Discovery and Medicine as well as a Q3 ranking in Pharmacology, Fitoterapia plays a vital role in promoting innovative research in the intersection of traditional medicine and modern pharmacological science. The journal’s commitment to quality is further highlighted by its rankings in Scopus, where it holds a notable position among peers in its field. Although Fitoterapia does not currently offer Open Access, its reputation for rigor and relevance makes it an indispensable asset for anyone engaged in herbal medicine research and development. Authors and researchers seeking to publish groundbreaking findings will find a welcoming platform to disseminate their work in this influential journal.

Chemical Biology & Drug Design

Fostering breakthroughs in molecular medicine and drug design.
Publisher: WILEYISSN: 1747-0277Frequency: 12 issues/year

Chemical Biology & Drug Design, an esteemed publication by WILEY, serves as a vital platform for the dissemination of pioneering research in the interdisciplinary fields of biochemistry, drug discovery, molecular medicine, organic chemistry, and pharmacology. With a dedicated commitment to advancing the understanding of chemical interactions and drug development, this journal not only fosters innovation but also bridges the gap between theoretical research and practical applications. It boasts an impressive impact factor and is recognized in the 2023 category quartiles as Q3 in Biochemistry and Molecular Medicine, and Q2 in Drug Discovery, Organic Chemistry, and Pharmacology, indicating its relevance and influence in these crucial areas. The journal’s rankings across various Scopus categories further solidify its position as a reputable resource for researchers, professionals, and students striving to stay at the forefront of medicinal chemistry and drug design. While primarily traditional access-based, the journal's evolving scope from 2006 to 2024 ensures an ongoing contribution to essential scientific dialogue, making it an indispensable read for those committed to advancing health sciences.

RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY

Pioneering Discoveries in Biochemistry and Organic Chemistry
Publisher: MAIK NAUKA/INTERPERIODICA/SPRINGERISSN: 1068-1620Frequency: 7 issues/year

Russian Journal of Bioorganic Chemistry (ISSN: 1068-1620, E-ISSN: 1608-330X), published by MAIK Nauka/Interperiodica/Springer, serves as a vital resource for researchers and professionals in the fields of bioorganic chemistry, biochemistry, and organic chemistry. With a focus on the integration of organic chemistry principles with biological processes, this journal aims to disseminate significant findings and advancements from both theoretical and practical perspectives. Although currently not open access, the journal retains a dedication to high-quality, peer-reviewed content, contributing to its reputation within the academic community. The 2023 Scopus rankings position it within the Q4 category for both biochemistry and organic chemistry, indicating its critical niche within these disciplines amid a competitive landscape. Since its inception in 1996, the journal has continued to evolve, providing enriching insights and fostering collaborations among scholars and practitioners alike, with publication converging up to the year 2024. By exploring complex biomolecular interactions and the synthesis of biologically relevant compounds, the Russian Journal of Bioorganic Chemistry remains a significant platform for advancing knowledge and innovation in the life sciences.

ACTA PHARMACOLOGICA SINICA

Unveiling Breakthroughs in Medicine and Pharmacology
Publisher: NATURE PUBL GROUPISSN: 1671-4083Frequency: 12 issues/year

ACTA PHARMACOLOGICA SINICA is a premier journal in the field of pharmacology, published by the esteemed Nature Publishing Group. With a strong history since its inception in 1980, this journal is recognized for its impactful contributions to the fields of medicine and pharmacology, consistently securing a Q1 ranking in multiple relevant categories, including Pharmacology (Medical). Drawing on a robust international readership, it ranks impressively at #8 out of 272 in the specialty of Medical Pharmacology, placing it in the top 97th percentile according to Scopus data. Although currently not an open-access publication, ACTA PHARMACOLOGICA SINICA remains a vital resource for researchers, professionals, and students seeking to advance their understanding of pharmacological sciences. Its commitment to disseminating high-quality research underscores its significance in fostering innovation and exploration in the medical landscape.

ANTICANCER RESEARCH

Connecting Knowledge to Combat Cancer
Publisher: INT INST ANTICANCER RESEARCHISSN: 0250-7005Frequency: 12 issues/year

ANTICANCER RESEARCH, published by the International Institute of Anticancer Research, stands at the forefront of cancer-related scholarly communication. With ISSN 0250-7005 and E-ISSN 1791-7530, this esteemed journal has been serving the global research community since 1981, showcasing innovative research aimed at combating cancer through various therapeutic approaches and scientific inquiry. Based in Greece, the journal aims to disseminate vital findings in the fields of Cancer Research, Medicine, and Oncology, reflecting its notable categorization in the Q3 and Q2 quartiles as of 2023. Despite its rigorous peer-review process and the absence of open access, ANTICANCER RESEARCH remains a vital publication for researchers, clinicians, and students eager to stay updated on the evolving landscape of anticancer strategies. As it converges to its milestone year of 2024, the journal continues to enrich the discourse around cancer treatment and prevention, affirming its position as an essential resource for those dedicated to advancing knowledge in anticancer therapies.

JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS

Advancing the Frontiers of Biological Regulation.
Publisher: BIOLIFE SASISSN: 0393-974XFrequency: 6 issues/year

JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, published by BIOLIFE SAS, is a pivotal platform in the fields of Cancer Research, Endocrinology, Immunology, and Physiology, addressing fundamental aspects of biological regulation and homeostasis. Since its inception in 1987, this journal has consistently contributed to the advancement of knowledge, showcasing innovative research and breakthroughs that are instrumental for professionals, researchers, and students alike. Although categorized in the Q4 quartile across multiple disciplines, the journal offers a unique perspective that encourages exploration into underrepresented areas, underscoring its role in fostering scientific dialogue and collaboration. With ISSN 0393-974X and E-ISSN 1724-6083, the journal remains a crucial resource for those invested in understanding the complexities of homeostatic agents and their implications in health and disease. Based in Silva Marina, Italy, it invites contributions that broaden the horizons of contemporary biomedical research.

BIOORGANIC & MEDICINAL CHEMISTRY

Connecting Molecular Insights to Clinical Applications
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0968-0896Frequency: 24 issues/year

BIOORGANIC & MEDICINAL CHEMISTRY, published by Pergamon-Elsevier Science Ltd, is a prominent journal in the fields of biochemical research and drug discovery, with an ISSN of 0968-0896 and an E-ISSN of 1464-3391. Established in 1993, it has garnered respect and recognition, evidenced by its categorization in various quartile ranks across 2023, including Q2 in Clinical Biochemistry and Pharmaceutical Science. It holds significant Scopus rankings, placing it in the 75th percentile in Pharmaceutical Science and 74th percentile in Organic Chemistry, highlighting its influential contributions to ongoing research and developments. This journal provides a platform for disseminating advancements in bioorganic and medicinal chemistry, focusing on innovative methodologies, therapeutic advancements, and molecular pharmacology. Although it does not follow an open-access model, it remains a key resource for researchers, professionals, and students aiming to stay at the forefront of scientific discovery in the UK and beyond. The journal’s commitment to enhancing knowledge within the biomedical community makes it an essential read for those passionate about this dynamic field.

CHEMICO-BIOLOGICAL INTERACTIONS

Advancing Understanding in Pharmacology and Toxicology
Publisher: ELSEVIER IRELAND LTDISSN: 0009-2797Frequency: 18 issues/year

CHEMICO-BIOLOGICAL INTERACTIONS is a premier journal published by Elsevier Ireland Ltd, dedicated to advancing the field of chemical and biological interactions since its inception in 1969. With a robust focus on pharmacology and toxicology, the journal holds a prestigious Q1 ranking in both Medicine (miscellaneous) and Toxicology, reflecting its significance in disseminating influential research. As part of the Scopus database, it ranks #21 out of 133 journals in Toxicology, positioning it in the 84th percentile and ensuring high visibility for cutting-edge studies. This scholarly platform serves as a crucial resource for researchers, professionals, and students who seek reliable and innovative findings at the intersection of chemistry and biology. While currently not open access, CHEMICO-BIOLOGICAL INTERACTIONS provides a comprehensive collection of articles that contribute to the ongoing dialogue in toxin research and its implications on medicinal chemistry, thereby fostering advancements in public health and safety.